(Q34760593)

4 August 2017

Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines (English)

1 reference

4 August 2017

1 reference

1 reference

14

Jorge S Reis-Filho

1 reference

4 August 2017

13

Alan Ashworth

1 reference

4 August 2017

6

Rachael Natrajan

1 reference

4 August 2017

12

Mitch Dowsett

1 reference

4 August 2017

11

Chris Jones

1 reference

4 August 2017

2

Caterina Marchio

1 reference

4 August 2017

3

David S P Tan

1 reference

4 August 2017

5

Maryou B Lambros

1 reference

4 August 2017

10

Kerry Fenwick

1 reference

Socorro Maria Rodriguez-Pinilla

4 August 2017

series ordinal

7

object named as

Socorro Maria Rodriguez-Pinilla

1 reference

4 August 2017

9

Narinder Tamber

1 reference

4 August 2017

Edurne Arriola

1

1 reference

4 August 2017

Suzanne C Drury

series ordinal

4

1 reference

4 August 2017

Alan Mackay

series ordinal

8

1 reference

4 August 2017

10 March 2008

1 reference

4 August 2017

Laboratory Investigation

1 reference

4 August 2017

88

1 reference

4 August 2017

5

1 reference

4 August 2017

491-503

1 reference

https://scigraph.springernature.com/pub.10.1038/labinvest.2008.19

4 August 2017

0 references

cites work

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.19

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.19

HER2 and responsiveness of breast cancer to adjuvant chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.19

retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil:

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.19

Amplification of a 280-Kilobase Core Region at the ERBB2 Locus Leads to Activation of Two Hypothetical Proteins in Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.19

Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.19

Genomic and expression profiling of chromosome 17 in breast cancer reveals complex patterns of alterations and novel candidate genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.19

A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.19

A multiplex PCR predictor for aCGH success of FFPE samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.19

Genomic and transcriptional aberrations linked to breast cancer pathophysiologies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.19

Evaluation of Phi29-based whole-genome amplification for microarray-based comparative genomic hybridisation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.19

Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.19

Novel patterns of genome rearrangement and their association with survival in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.19

Using array-comparative genomic hybridization to define molecular portraits of primary breast cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.19

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.19

Global variation in copy number in the human genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.19

A comprehensive analysis of common copy-number variations in the human genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.19

Molecular evolution of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.19

RNA interference-based functional dissection of the 17q12 amplicon in breast cancer reveals contribution of coamplified genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.19

Combination treatment with Grb7 peptide and Doxorubicin or Trastuzumab (Herceptin) results in cooperative cell growth inhibition in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.19

Metastatic Lymph Node 51, a novel nucleo-cytoplasmic protein overexpressed in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.19

The SWI/SNF chromatin remodeling subunit BAF57 is a critical regulator of estrogen receptor function in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.19

Oncogenic activity of Cdc6 through repression of the INK4/ARF locus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.19

Topoisomerase II-alpha gene deletion is not frequent as its amplification in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.19

Survivin is an independent predictor of short-term survival in poor prognostic breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.19

Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.19

YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.19

It's about time: scheduling alters effect of histone deacetylase inhibitors on camptothecin-treated cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.19

Distinct ErbB-2 coupled signaling pathways promote mammary tumors with unique pathologic and transcriptional profiles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.19

Phosphorylation of PEA-15 switches its binding specificity from ERK/MAPK to FADD

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.19

Pleomorphic lobular carcinoma of the breast: role of comprehensive molecular pathology in characterization of an entity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.19

c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.19

7 January 2021

erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.19

7 January 2021

Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.19

7 January 2021

Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.19

7 January 2021

Predictive value of HER-2 and Topoisomerase IIalpha in response to primary doxorubicin in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.19

7 January 2021

Ductal invasive G2 and G3 carcinomas of the breast are the end stages of at least two different lines of genetic evolution

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.19

7 January 2021

The incidence of topoisomerase II-alpha genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplification: a fluorescence in situ hybridization study

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2008.19

7 January 2021

10.1038/LABINVEST.2008.19

Identifiers

DOI

1 reference

Dimensions Publication ID

4 August 2017

0 references

1 reference